Swiss CDMO giant Lonza announced Monday that it’s partnering with GE Healthcare to build a new biomanufacturing facility in China.
Lonza is one of several companies looking to increase their footprint in China as the regulatory environment becomes more favorable for manufacturing.
The roughly 17,000 square meter facility will include 6,500 square meters of lab space, and 1,000 and 2,000-liter bioreactors. Lonza plans to primarily make anitbodies at the facility, which will be located in Guangzhou, a port city outside of Hong Kong.
Lonza says it will employ about 160 workers at the site which will become fully operational by 2020.
Read the press release.